Sanofi ThiNKs Scribe’s CRISPR Approach Can Advance Its NK Cell Therapy Goals

 
• By Joseph Haas

Deal Snapshot: CRISPR-Cas9 co-inventor Jennifer Doudna-founded gene-editing firm inks its second large collaboration, teaming with Sanofi on off-the-shelf natural killer cell therapies for cancer.

Cancer cell therapy
Sanofi will call on Scribe's gene-editing expertise for its NK cancer cell therapy efforts • Source: Shutterstock

More from Deals

More from Business